Wave Life Sciences Ltd. Share Price & Technical Analysis
WVE · $6.38 (-0.62%)
Healthcare / Biotechnology
$6.38
-0.62%
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disor…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-10% return in May, 1% avg return in past 3 year May month.
-73% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -24% | 9% | -47% | -1% | -10% | – | – | – | – | – | – | – | -73% |
| 25 | -7% | -7% | -24% | -3% | -22% | 7% | 25% | 20% | -23% | 23% | -12% | 124% | 100% |
| 24 | -14% | 9% | 29% | -21% | 27% | -19% | 35% | -12% | 44% | 67% | 9% | -20% | 132% |
| 23 | -31% | -19% | 2% | -9% | 0% | -10% | 22% | 0% | 32% | -5% | -2% | -4% | -24% |
| 22 | -29% | 14% | -17% | -5% | -26% | 129% | -24% | 20% | 24% | 33% | -12% | 67% | 173% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.33B
P/E ratio
—
52W high
$21.73
52W low
$5.02
Volume
23,86,450
Beta
-1.32
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Wave Life Sciences Ltd. share price today?
- Wave Life Sciences Ltd. (WVE) last traded around $6.38 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does WVE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for WVE. Download the app for real-time alerts.
- How can I analyze Wave Life Sciences Ltd. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.